Bladder Large Cell Neuroendocrine Carcinoma(LCNEC): A Case Report of Exfoliated Cytology and Pathological Characteristics.

J Vis ExpSep 18, 2026 (epub)
Case ReportOncology (Medical)UrologyPathology (Anatomic & Clinical)

Yu He, Huazhen Kong, Cui Zhang et al.

✦ AI-curated · Sources linked

Case in brief

A 77-year-old man presented with recurrent gross hematuria, urinary frequency, urgency, and lumbosacral pain. Imaging revealed a large soft-tissue mass on the bladder wall. Urine cytology showed atypical tumor cells, leading to a diagnosis of primary bladder large cell neuroendocrine carcinoma (LCNEC) after transurethral resection. The patient received adjuvant chemotherapy but experienced tumor recurrence at the 3-month follow-up.

Diagnostic / clinical pearl

Urine exfoliative cytology can effectively detect high-grade malignant cells in the urinary tract, particularly in cases lacking specific clinical and imaging features.

Why it matters

This case highlights the importance of integrating histopathology and immunohistochemistry for the definitive diagnosis of rare malignancies like bladder LCNEC.

Source

PubMed · PMID 42762149

Published in J Vis Exp. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.